Envista Holdings Co. (NYSE:NVST) Given Average Recommendation of "Hold" by Brokerages

Shares of Envista Holdings Co. (NYSE:NVST - Get Free Report) have been assigned an average recommendation of "Hold" from the fifteen research firms that are covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have issued a buy rating on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $20.18.

Several brokerages recently commented on NVST. Morgan Stanley reduced their target price on Envista from $20.00 to $19.00 and set an "equal weight" rating for the company in a research report on Thursday, March 6th. Jefferies Financial Group lifted their price objective on Envista from $20.00 to $22.00 and gave the company a "hold" rating in a report on Thursday, January 23rd. UBS Group cut their price objective on Envista from $23.00 to $21.00 and set a "neutral" rating for the company in a report on Monday, March 10th. Wells Fargo & Company set a $19.00 price objective on Envista in a report on Saturday, March 8th. Finally, Piper Sandler lifted their price objective on Envista from $17.00 to $18.00 and gave the company a "neutral" rating in a report on Monday, February 3rd.

Envista Stock Performance

Shares of Envista stock traded down $0.27 during midday trading on Friday, hitting $16.90. The company had a trading volume of 2,055,352 shares, compared to its average volume of 2,282,663. The stock has a market cap of $2.91 billion, a PE ratio of -2.60, a P/E/G ratio of 1.27 and a beta of 1.33. Envista has a 1-year low of $15.15 and a 1-year high of $23.00. The business's 50 day simple moving average is $19.94 and its two-hundred day simple moving average is $19.64. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.04 and a quick ratio of 1.76.

Remove Ads

Envista (NYSE:NVST - Get Free Report) last issued its earnings results on Wednesday, February 5th. The company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. As a group, equities analysts predict that Envista will post 1 EPS for the current fiscal year.

Institutional Trading of Envista

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Ariel Investments LLC increased its position in Envista by 6.2% in the fourth quarter. Ariel Investments LLC now owns 12,059,624 shares of the company's stock worth $232,630,000 after purchasing an additional 699,625 shares during the period. Nuance Investments LLC increased its position in Envista by 4.4% in the third quarter. Nuance Investments LLC now owns 7,346,534 shares of the company's stock worth $145,168,000 after purchasing an additional 308,221 shares during the period. Franklin Resources Inc. grew its position in shares of Envista by 72.6% during the 4th quarter. Franklin Resources Inc. now owns 6,854,506 shares of the company's stock worth $132,223,000 after buying an additional 2,882,844 shares during the period. Dimensional Fund Advisors LP grew its position in shares of Envista by 19.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 6,762,091 shares of the company's stock worth $130,440,000 after buying an additional 1,089,923 shares during the period. Finally, Gates Capital Management Inc. grew its position in shares of Envista by 15.1% during the 4th quarter. Gates Capital Management Inc. now owns 4,694,148 shares of the company's stock worth $90,550,000 after buying an additional 615,577 shares during the period.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.